Eurobio Scientific GmbH (formerly Myriad International GmbH) has been a subsidiary of Eurobio Scientific in Francesince 2024. Eurobio Scientific GmbH was the first company worldwide to establish the analysis of RNA from fixed tumor tissue as an in vitro diagnostic method for decentralized use, with the introduction of the EndoPredict test.

Gene expression tests support critical treatment decisions in early-stage breast cancer. By detecting the risk of breast cancer recurrence, these tests help avoid both over- and undertreatment, along with the potentially life-altering consequences such decisions may have on a woman’s life—now and in the future.

The EndoPredict Breast Cancer Prognostic Test is the most precise gene expression test for predicting the recurrence of early-stage breast cancer. It assists in guiding treatment decisions for eligible patients with ER-positive/HER2-negative primary invasive breast cancer. Eurobio Scientific is committed to helping define the optimal treatment pathway for every woman.

Prolaris® was the first test to offer a direct measurement of the molecular biology of an individual’s prostate cancer. By quantifying the expression levels of genes involved in cancer cell proliferation, Prolaris provides an accurate assessment of disease aggressiveness. It has proven to be the most clinically significant prognostic marker at the time of diagnosis.

The test offers unique, additional information alongside standard clinical factors, enabling the most precise prediction of a patient’s prostate cancer aggressiveness. Prolaris has been extensively validated in diverse patient cohorts under both conservative management (non-surgical approaches) and definitive therapies such as surgery or radiation.

‍

‍